1. Home
  2. CDNA vs ANNX Comparison

CDNA vs ANNX Comparison

Compare CDNA & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$21.55

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.48

Market Cap

972.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDNA
ANNX
Founded
1998
2011
Country
United States
United States
Employees
765
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
972.5M
IPO Year
2007
2020

Fundamental Metrics

Financial Performance
Metric
CDNA
ANNX
Price
$21.55
$5.48
Analyst Decision
Buy
Strong Buy
Analyst Count
6
6
Target Price
$28.00
$16.50
AVG Volume (30 Days)
744.0K
2.0M
Earning Date
04-28-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
$48,324,000.00
N/A
Revenue This Year
$16.01
N/A
Revenue Next Year
$11.31
$16,320.74
P/E Ratio
$430.00
N/A
Revenue Growth
18.93
N/A
52 Week Low
$10.96
$1.85
52 Week High
$23.24
$7.18

Technical Indicators

Market Signals
Indicator
CDNA
ANNX
Relative Strength Index (RSI) 58.59 41.02
Support Level $16.63 $4.79
Resistance Level $23.19 $5.61
Average True Range (ATR) 1.46 0.30
MACD -0.04 -0.07
Stochastic Oscillator 66.57 15.79

Price Performance

Historical Comparison
CDNA
ANNX

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: